N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=48 Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
Phase 2 N=79 Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Gastroparesis
Primary: Gastric Half Emptying Time (GEt1/2) — 131.2; 106.5; 118.2; 131.1 Minutes
Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
N/A N=20 Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility
Gastroparesis · Dyspepsia
Primary: Frequency of Contractions at Baseline — 20; 24.6; 23.7 stomach contractions/minute
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
Phase 2 N=104 Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
Dyspepsia · Diabetes Mellitus With Gastrointestinal Symptoms
Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06
Phase 2 N=57 A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Gastroparesis
Primary: Dose-normalized Levodopa (L-DOPA) Area Under the Plasma Concentration-time Curve From Zero to 4 Hours AUC(0-4) at Baseline — 24.13; 24.81…
N/A N=88 Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol
Gastrointestinal Diseases
Primary: Device Success Defined as the Ability to Record Myoelectric Signals in Study Subjects. — 88 participants
Phase 4 N=3 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Cystic Fibrosis Gastrointestinal Disease
Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours
Phase 4 N=22 Effect of Dexmedetomidine of Gastrointestinal Motility
Anesthesia
Primary: Intra-anal Sphincter Pressure (IASP) 1 Minute After Dexmedetomidine Administration — 62.9 mmHg
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours
N/A N=24 Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers
Gastroparesis
Primary: Gastroduodenal Manometry Measurement — 9.862; 10.38; 10.38; 8.433 motility index units (see Description)
Phase 3 N=37 Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
Chronic Idiopathic Constipation
Primary: Time Reduction (Hours and Minutes) of Gastric Emptying (GE), Small Bowel (SB), Large Bowel (LB) and Whole Gut (WG) Transits Measured by SmartPill in Chronically…
Phase 4 N=13 Effect of Octreotide on the Colonic Motility in Pediatric Patients
Colonic Motility Index · Constipation
Primary: Compared Colonic Motility Index From Fasting to Post Octreotide Infusion — 6.03; 6.89; 7.73; 5.32 mm Hg — p=0.087
N/A N=1,881 Impact of Diet on Functional Gastrointestinal Symptoms
Gastrointestinal Disorder, Functional
Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants
Phase 2 N=46 Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
Irritable Bowel Syndrome Constipation Predominant
Primary: Colonic Transit, Colonic Geometric Center at 24 Hours — 2.39; 2.37; 2.02; 1.76 units on a scale
N/A N=4 Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Constipation-predominant Irritable Bowel Syndrome
Primary: A Change in Length of Spread of Antegrade Contractions After Placebo.
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
N/A N=2 Stimulation for Colonic Motility
Neurogenic Bowel Dysfunction
Primary: Compare Changes in Number of Interventions Used to Complete Bowel Routine, Including Electrical Rectal Stimulation (Treatment) Versus Mechanical Rectal Distension…
Phase 3 N=40 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
Healthy
Primary: Gastric Volume — 262; 718 mL — p=<0.0001
Phase 3 N=130 Nortriptyline for Idiopathic Gastroparesis
Idiopathic Gastroparesis
Primary: Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits — 15; 14 participants — p=0.86
N/A N=76 Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch
Idiopathic Parkinson's Disease
Primary: Change From Baseline to Visit 3 in the Assessment of Intensity of Gastrointestinal (GI) Complaints for Any Reason as Per Visual Analogue Scale (VAS) — -26.8 millimeter…
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
Phase 2 N=36 Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids — 3.5; -19.8; -25.4; -25.7 percent change — p=0.0012
Phase 2 N=110 Metoclopramide Versus Placebo for GJ Placement
Radiation Exposure · Enteral Nutrition
Primary: Time to Duodenal Intubation — 1.6; 4.1 Minutes
Early Phase 1 N=14 Pioglitazone for Idiopathic Gastroparesis
Gastroparesis
Primary: Severity of Gastrointestinal Symptoms as Assessed by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index — 2.9; 2.3; 2.2; 2.6…
Phase 4 N=60 Lubiprostone, Colonic Motility and Sensation
Healthy
Primary: Colonic Compliance — 16.60; 16.50 mm Hg
Phase 2 N=36 Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome
Primary: Colonic Transit Geometric Center at 24 Hours — 3.12; 3.05; 2.77 units on a scale
N/A N=9 Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Patients With Gastroparesis Who Have Failed Standard Therapy
Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants